Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.